Journal
SAUDI JOURNAL OF GASTROENTEROLOGY
Volume 18, Issue 3, Pages 155-167Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/1319-3767.96445
Keywords
Antifibrotic strategies; biochemical abnormalities; cell types; gene therapy; hepatic fibrosis
Categories
Funding
- University Grants Commission (UGC) [DS Kothari-PDF]
- Department of Science & Technology (DST)
- Ministry of Science & Technology, New Delhi [DST/INSPIRE/2010/121]
Ask authors/readers for more resources
Hepatic fibrosis (HF) is a progressive condition with serious clinical complications arising from abnormal proliferation and amassing of tough fibrous scar tissue. This defiance of collagen fibers becomes fatal due to ultimate failure of liver functions. Participation of various cell types, interlinked cellular events, and large number of mediator molecules make the fibrotic process enormously complex and dynamic. However, with better appreciation of underlying cellular and molecular mechanisms of fibrosis, the assumption that T-IF cannot be cured is gradually changing. Recent findings have underlined the therapeutic potential of a number of synthetic compounds as well as plant derivatives for cessation or even the reversal of the processes that transforms the liver into fibrotic tissue. It is expected that future inputs will provide a conceptual framework to develop more specific strategies that would facilitate the assessment of risk factors, shortlist early diagnosis biomarkers, and eventually guide development of effective therapeutic alternatives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available